



## ASX Announcement

### Renounceable Rights Issue – Share Allotment

**19 May 2011, Melbourne, Australia:** Benitec Ltd (ASX:BLT), a world leader in RNA-based gene silencing for human therapeutics, today announced that it has completed the Renounceable Rights Issue and Shortfall Offer under the Offer Document dated 11 April 2011. Benitec further advises that allotments have been completed today and despatch of holding statements will be completed by 20 May 2011 in accordance with the published timetable.

Pursuant to the ASX Listing Rules, the company advises the following:

#### 1. The date of allotment and number of securities:

- Allotment date: 19 May 2011.
- Number of securities issued: 404,565,857 fully paid ordinary shares issued at \$0.02 per share and 101,141,555 listed options with expiry date of 31 December 2013 and exercise price of \$0.04.
- Despatch of Holding Statements: 20 May 2011.
- A further 100,160,983 listed options, being the sub-writer options, will be allotted by end of day tomorrow.

#### 2. Issued Capital of the Company following the above issue and allotment:

##### SHARES

910,272,729 Fully Paid Ordinary Shares (ASX code: BLT)

##### OPTIONS

46,673,907	Listed Options, exercise price \$0.10, expiry date 8 April 2014 (ASX code: BLTO)
201,302,538	Listed Options, exercise price \$0.04, expiry date 31 December 2013 (ASX code: BLTOB)
7,560	Unlisted Options, exercise price \$0.03, expiry date 30 September 2013
6,126,962	Unlisted Options, exercise price \$0.90, expiry date 4 August 2014
1,953,125	Unlisted Options, exercise price \$0.17, expiry date 23 October 2015
1,000,000	Unlisted Options, exercise price \$0.0407*, expiry date 14 December 2011
4,666,666	Unlisted Options, exercise price \$0.0889*, expiry date 31 December 2012
300,000	Unlisted Options, exercise price \$0.0781*, expiry date 21 February 2013
22,244,444	Unlisted Options, exercise price \$0.10, expiry date 31 December 2012
120,000	Unlisted Options, exercise price \$0.10, expiry date 10 April 2015
6,500,000	Unlisted Options, exercise price \$0.0204*, expiry date 19 August 2014
3,000,000	Unlisted Options, exercise price \$0.0228*, expiry date 19 August 2014
3,000,000	Unlisted Options, exercise price \$0.0289*, expiry date 9 June 2013

\* Please note that, following the Renounceable Rights Issue, the exercise price for Non-Executive Options and ESOP Options have changed pursuant to their terms and conditions.

A statement setting out the names of the 20 largest holders of fully paid ordinary shares and the percentage held by each following the allotment is attached as Annexure 1.

## **About Benitec**      [www.benitec.com](http://www.benitec.com)

Benitec Limited is developing new novel treatments for chronic and life-threatening conditions based on a transformational technology, DNA-directed RNA interference (ddRNAi) - sometimes called expressed RNAi. The technology's potential to address unmet medical needs and, potentially, to cure disease results from its demonstrated ability to permanently silence genes which cause the condition.

Benitec now either owns or exclusively licences from CSIRO more than 40 granted or allowed patents in the field of RNA interference for human therapeutic applications. Patents have been granted in key territories such as the USA, the UK, Japan, Europe, Canada and Australia. In addition, Benitec has almost 50 patent applications pending for which it is the owner or exclusive licensee from CSIRO, and has further intellectual property under development as a result of its pipeline program.

Benitec trades on the Australian stock exchange under the symbol "BLT". The Company was founded in 1997 and has been publicly held since 2001. The Company aims to deliver a range of novel ddRNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry. In-house it is pursuing a focused R&D strategy in infectious diseases, cancer and chronic cancer-associated pain, as well as programs with licensees that have advanced to pre-clinical and/or clinical trials.

## **For Further Information**

Dr Peter French  
Chief Executive Officer  
Tel: +61 (0)412 457 595

[pfrench@benitec.com](mailto:pfrench@benitec.com)

**Media enquiries:**  
College Hill Life Sciences  
Sue Charles (Global)  
Tel: +44 (0)7968 726585

[benitec@collegehill.com](mailto:benitec@collegehill.com)

Daniel Gooch (Europe)  
Tel: +44 (0)20 7866 7866

Andrew Geddes (Australia)  
Tel: +61 (0)408 677 734

Rebecca Skye Dietrich (US)  
Tel: +1 (857) 241 0795

**TOP 20 SHAREHOLDERS as at 19 May 2011 (ASX CODE: BLT)**

<b>HOLDER NAME</b>	<b>NO. OF SHARES</b>	<b>%</b>
Dr Christopher Bremner	192,637,678	21.2%
CSIRO	48,116,431	5.3%
JP Morgan Nominees Australia Limited	36,275,854	4.0%
Klip Pty Ltd	26,627,402	2.9%
Citicorp Nominees Pty Limited	25,169,295	2.8%
Sigma-Aldrich Pty Limited	19,531,250	2.2%
Promega Corporation	12,996,339	1.4%
UBS Wealth Management Australia Nominees Pty Ltd	11,560,243	1.3%
MGL Corp Pty Ltd	8,936,000	1.0%
Mr Chris Retzos	6,838,201	0.8%
HSBC Custody Nominees (Australia) Limited	6,684,843	0.7%
Mr Aron Malcolm	5,672,420	0.6%
Mr Paul Leonard Grimshaw & Mr Dayne Paul Grimshaw	5,176,283	0.6%
La Jolla Cove Investors Inc	5,093,289	0.6%
Mambat Pty Ltd	5,000,000	0.5%
Mr Trevor Harold Ahern & Mrs Suzanne Margaret Ahern	4,664,430	0.5%
Mr Eric Ross MacDonald & Mrs Annalisa MacDonald	4,600,000	0.5%
Commsec Nominees Pty Limited	4,533,250	0.5%
RWD Nominees Pty Ltd	4,477,000	0.5%
Blamco Trading Pty Ltd	4,000,000	0.4%
<b>TOTAL FOR TOP 20</b>	<b>438,550,208</b>	<b>48.2%</b>
<b>TOTAL SHARES ON ISSUE</b>	<b>910,272,729</b>	